Leiping Wang

New approaches and procedures for cancer treatment: Current perspectives

Reciprocal Regulation of DUSP9 and DUSP16 Expression by HIF1 Controls ERK and p38 MAP Kinase Activity and Mediates Chemotherapy-Induced Breast Cancer Stem Cell Enrichment

Triple-negative breast cancer: is there a treatment on the horizon?

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

Original paper Prognostic value of PIK3CA mutation status, PTEN and androgen receptor expression for metastasis-free survival in HER2-positive breast cancer patients treated with trastuzumab in adjuvant setting

Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib

Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy

Triple-negative breast cancer molecular subtyping and treatment progress

Combination of Antibody That Inhibits Ligand-Independent HER3 Dimerization and a p110α Inhibitor Potently Blocks PI3K Signaling and Growth of HER2+ Breast Cancers

Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer

PIK3CA mutations in breast cancer: reconciling findings from preclinical and clinical data

Breast cancer

Inflammation and tumor progression: signaling pathways and targeted intervention

Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway

Cytotoxic chemotherapy: Still the mainstay of clinical practice for all subtypes metastatic breast cancer

Pyroptosis: A new frontier in cancer

The PI3K Pathway in Human Disease

Targeting immune cells for cancer therapy

A review of energy systems models in the UK: Prevalent usage and categorisation

A review of the circular economy in China: moving from rhetoric to implementation

Aloe‐emodin: A review of its pharmacology, toxicity, and pharmacokinetics

Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors

Cancer Nanomedicine: A New Era of Successful Targeted Therapy

Energy security in China: A quantitative analysis and policy implications

Modelling energy demand of developing countries: Are the specific features adequately captured?

Reactive Oxygen Species (ROS)-Based Nanomedicine

China's ongoing energy efficiency drive: Origins, progress and prospects

Analysis of nanoparticle delivery to tumours

Bridging the Knowledge of Different Worlds to Understand the Big Picture of Cancer Nanomedicines

Reactive oxygen species generating systems meeting challenges of photodynamic cancer therapy

Energy models for demand forecasting—A review

Clinical Translation of Nanomedicine

Sustainable Energy in China : The Closing Window of Opportunity

Overall survival of cancer patients with serum lactate dehydrogenase greater than 1000 IU/L

Cisplatin improves antitumor activity of weekly nab-paclitaxel in patients with metastatic breast cancer

PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib

Cisplatin and gemcitabine as the first line therapy in metastatic triple negative breast cancer

Chemotherapy of metastatic triple negative breast cancer: Experience of using platinum-based chemotherapy

Abraxane® versus Taxol® for patients with advanced breast cancer: A prospective time and motion analysis from a Chinese health care perspective